Eva Blondeaux 1, Amir Sonnenblick 2, Elisa Agostinetto . Lancet Oncol. 2025 Jun;26(6):759-770
The BRCA BCY Collaboration is an international, hospital-based, retrospective cohort study, conducted at 109 centers in five continents, including women harboring germline BRCA1, BRCA2, or both, pathogenic or likely pathogenic variants and diagnosed with stage I–III invasive breast cancer at the age of 40 years or younger between Jan 1, 2000, and Dec 31, 2020. The primary objectives of the present analysis were to determine the association between RRM or RRSO and overall survival in young BRCA carriers with breast cancer. The primary endpoint was overall survival. Between Jan 1, 2000, and Dec 31, 2020, 5290 patients were included, of whom 3361 (63·5%) patients were BRCA1 pathogenic variant carriers, 2708 (51·2%) had node-negative, and 2421 (45·8%) hormone receptor-positive breast cancer. Of 5290 patients, 2910 (55·0%) underwent RRM, 2782 (52·6%) underwent RRSO. After a median follow-up of 8·2 years, RRM was associated with significantly better overall survival compared with no RRM (adjusted HR 0·65; 20-year restricted mean overall survival time 17·89 years with RRM vs 16·65 years without RRM). RRSO was also associated with significantly better overall survival compared with no RRSO (HR 0·58, 95%; 20-year restricted mean overall survival time 17·73 years with RRSO vs 16·67 years without RRSO. In this global cohort of BRCA carriers with previous breast cancer diagnosis at a young age, RRM and RRSO were both associated with a significant improvement in overall survival. These findings provide evidence for a tailored counselling of a unique and high-risk patient population on cancer risk management strategies
24 Mar, 2026